Skip To Main Content
Theo Rispens on Muck Rack

Theo Rispens

As seen in: Nature, Wiley Online Library, Memory Studies, Annals of the Rheumatic Diseases, JAMA (The Journal of the American Medical Association), MedPage Today, The Journal of Clinical Investigation, The Journal of Biological Chemistry, The Journal of Immunology, The Journal of Allergy & Clinical Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Theo

Contact Theo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis

|
By Theo Rispens, Sanquin Research, Landsteiner Laboratory, Amsterdam UMC
| JAMA (The Journal of the American Medical Association) Verified
Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis Natalizumab is an effective therapy for patients with relapsing-remitting multiple sclerosis (MS) but increases the risk of progressive multifocal leukoencephalopathy (PML).1 During treatment with Tysabri (Biogen), antibodies against the John Cunningham virus (JCV) are measured with the second-generation STRATIFY JCV DxSelect assay (Focus Diagnostics).
Open in Who Shared Issue with article?

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma

|
By Kyra A. Gelderman, Theo Rispens, Catharina M Korse, Ellen Kapiteijn
| bmj.com
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Open in Who Shared Issue with article?

Concentrations of subcutaneously administered belimumab in human breast milk of a woman with systemic lupus erythematosus: a case report

|
By Theo Rispens, Alexandre E. Voskuyl, Amsterdam UMC, Birgit S Blomjous
| bmj.com
Lupus Erythematosus, Systemic Pharmacokinetics Antibodies Antirheumatic Agents Belimumab is a human immunoglobulin G1 (IgG1)-lambda monoclonal antibody that inhibits the B-cell survival factor BLyS. It is used as an add-on therapy in patients with active systemic lupus erythematosus (SLE), an autoimmune disease characterised by hyperactive B-cells. SLE affects mostly women in the fertile age and may flare up postpartum.
Open in Who Shared Issue with article?
See all 21 licensed articles (22 Total)